- ￥2980
- Bioss
- bs-1033R-PE
- 2025年10月15日
- 产品信息以Bioss网站为准
企业认证
相关产品推荐更多 >
PKC delta Rabbit pAb, PE conjugated(bs-23441R-PE)-100ul
￥2980phospho-Hsp90 beta (Ser226) Rabbit pAb, PE-Cy7 conjugated(bs-18074R-PE-Cy7)-100ul
￥2980
Mitoferrin 2/SLC25A28 Rabbit pAb, Biotin conjugated(bs-7157R-Bio)-100ul
￥2980NeuN Rabbit pAb, APC conjugated(bs-1613R-APC)-100ul
￥2980
GBA2 Rabbit pAb(bs-13297R)-50ul/100ul/200ul
￥1180
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 应用范围：
产品信息以Bioss网站为准
- 规格：
100ul
| 产品编号 | bs-1033R-PE |
| 英文名称 | KRAS Rabbit pAb, PE conjugated |
| 中文名称 | PE标记的原癌基因K-ras抗体 |
| 英文别名 | C-K-RAS; c-Ki-ras; c-Ki-ras p21; Ha-ras; K-RAS B; K-RAS2A; K-RAS2B; K-RAS4A; KI-RAS; KI-RAS4B; KRAS; KRAS1; KRAS2; MGC7141; NS; NS3; p21; p21B; p21ras; RAS; RAS1; RASH; RASK2. |
| 产品应用 | Flow-Cyt=1ug/Tset, IF=1:100-500 Not yet tested in other applications. |
| 抗体来源 | Rabbit |
| 免疫原 | KLH conjugated synthetic peptide derived from human K-ras |
| 亚型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 克隆类型 | Polyclonal |
| 浓度 | 1mg/ml |
| 储存液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 研究领域 | Cancer > Signal transduction > G protein signaling > Small G proteins > Ras family Epigenetics and Nuclear Signaling > Transcription > Cancer susceptibility > Proto-oncogenes Signal Transduction > Signaling Pathway > G Protein Signaling > Small G Proteins > Ras Family |
| 亚基 | In its GTP-bound form interacts with PLCE1. Interacts with TBC1D10C. Interacts with RGL3. Interacts with HSPD1. Found in a complex with at least BRAF, HRAS1, MAP2K1, MAPK3 and RGS14. Interacts (active GTP-bound form) with RGS14 (via RBD 1 domain). Forms a signaling complex with RASGRP1 and DGKZ. Interacts with RASSF5. Interacts with PDE6D. Interacts with IKZF3. Interacts with GNB2L1. |
| 亚细胞定位 | Cell membrane. Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus membrane; Lipid-anchor. Isoform 2: Nucleus. Cytoplasm. Cytoplasm, perinuclear region. |
| 组织特异性 | Widely expressed. |
| 相似性 | Belongs to the small GTPase superfamily. Ras family. |
| 功能 | Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. |
| 保存条件 | Shipped at 4℃. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 背景资料 | This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq]Ras, a proto-oncogene, is a small G-protein that has 3 primary isoforms (H-Ras, N-Ras, and K-Ras) that differ in there approximately 20 C-terminal amino acids. H-Ras was first discovered as a transforming product the retrovirus Harvey murine virus and K-Ras of Kirten sarcoma virus. Ras is a heavily studied target of both academic and pharmaceutical research because of its implications in various pathways and diseases as well as being mutated in a large number of human cancers. Ras is most notably the activator of the Erk/MAPK kinase pathway as activator of Raf, as well as an activator of PI3 Kinase (PI3K). In its oncogenic, mutated state, Ras is unable to hydrolyze GTP to GDP, thus staying in an active state and activating numerous pathways including the MAPK pathway through its activation of Raf, but also others as well that include PI3 Kinase and RalGDS. One path that the pharmaceutical industry has taken to control Ras and its activity is by finding what some consider its Achilles’ heel. For its activation, Ras must localize to the plasma membrane, but interestingly, it lacks a transmembrane domain. To achieve this, Ras must first undergo a post-translational modification (PTM) known as prenylation or geranylation at its C-terminal CAAX motif. For this to take place, a controlled three step process must occur. The first step in the process is the prenylation or geranylation of the C in the CAAX motif that is initiated by the covalent attachment of farnesyl groups to the cysteine that is catalyzed by the . After this modification, the and heterodimer enzymes farnesyl transferases –aaX of the motif is proteolytically removed via Rce1 (Ras Converting Enzyme 1), a membrane associated endoprotease, by a mechanism that is still not fully understood. Finally, the C-terminal prenylcysteine is now methlylated by ICMT (Isoprenylcysteine Carboxymethyl Transferase). These drugs have yet to pass clinical trials though and there is doubt that they will ever be successful in treating tumors associated with Ras activation. |
| 应用 | 推荐稀释比例 |
| {Flow-Cyt} | {1ug/Tset} |
| {IF} | {1:100-500} |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
KRAS Rabbit pAb, PE conjugated(bs-1033R-PE)-100ul
￥2980
